Glanbia's Pricing Power Under Record Whey Costs Drives Upgrade

Glanbia's first-half performance was a clear demonstration of pricing power in the face of record whey inflation. Adjusted EPS rose 30% constant currency, driven by strong growth across all three segments. The company upgraded its full-year EPS guidance to 17%–20% growth, citing whey protein demand that shows no signs of slackening. The PN margin story is one of offsetting cost pressure with decisive action: price increases, promotional efficiency, and the group-wide transformation program.

The Whey Conundrum Turns Into a Tailwind

The most striking change is the company's increasing confidence in the protein cycle. Management highlighted that

We are the biggest buyer of whey protein straight ingredients globally, and we work with all suppliers. And then we're one of the biggest in whey protein solutions to our Dairy Nutrition business. So certainly, there's a natural hedge across those 2 businesses, and it is a unique strength of our portfolio given the growth in health and wellness.

On the cost side, Mark Garvey confirmed in the current call that “we have procured all of our whey needs for 2026 and our anticipated needs to early Q2 2027” — Mark Garvey, CFO · 2026-08-06—a proactive hedge that gives visibility into 2027. Yet the pricing power is also visible in consumer behavior. As Hugh McGuire noted, “Optimum Nutrition demonstrated the highest resilience to pricing out of all brands tested” — Hugh McGuire, CEO · 2026-08-06, and the brand is recruiting new consumers at a record pace. The launch of smaller pack sizes is a deliberate effort to capture first-time buyers, with 80% of those purchases new to the brand.

Transformation and Portfolio Focus

The group-wide transformation program has been upgraded from $60 million to $70 million in annual savings by 2027, with 40% expected this year. This is delivering margin progression that partially offsets whey inflation. Meanwhile, the Health & Nutrition segment saw a 110bp EBITDA margin decline due to raw material costs, but management expects protein solutions business to benefit from capacity expansions in the U.S., Europe, and China coming onstream by early 2027.

Portfolio actions, including the sale of noncore brands, are also helping. The transformation savings are being reinvested 50% toward growth, particularly in digital marketing and innovation like creatine gummies and electrolyte powders.

Outlook and Risks

The upgraded guidance assumes some elasticity in the second half, as Mark Garvey warned: “We are executing further price increases in Q3 given continued whey inflation” — Mark Garvey, CFO · 2026-08-06 and expect volumes to moderate. The Middle East conflict is also a cost factor for Health & Nutrition, but the company expects to pass through pricing where needed. Notably, the global keyword Batch Zero (a theme from the broader market) is not directly relevant here, but tariff refunds are a shared theme across many reporters this quarter.

Prior calls have repeatedly emphasized whey cost headwinds and elasticity, with Mark Garvey noting in February 2026: “Costs continue to be elevated. There's obviously a 90 to 80 element to whey, and those have 80 have rising a bit more recently” — Mark Garvey, Chief Financial Officer · 2026-02-25. The difference now is the demand side: Hugh McGuire said on the same call, “We're moving into blends of whey and collagen, targeting hydration and recovery” — Hugh McGuire, Chief Executive Officer · 2026-02-25—a sign of proactive innovation to broaden the protein story beyond whey.

In sum, Glanbia is not just riding a cyclical tailwind; it is demonstrating structural pricing power and portfolio balance. The upgrade to 17–20% EPS growth is underpinned by the natural hedge, forward procurement, and a transformation program that is delivering ahead of plan. The key risk remains elasticity, but management's pragmatic approach—watching elasticity while still raising prices—suggests they are managing the cycle with discipline.